GI-1d-a: Comparison of estimates of people for dataset A (left bar) and B (right bar) per region. The largest discrepancies occur in areas of NE, SE and SW Germany and adjacent reg... by Isabell Schmidt (6331013)

Effect of supplementation of oocyte maturation medium (OMM) with follicular fluid (FF) from small or large follicles on development of embryos to the blastocyst stage. by Verónica M. Negrón-Pérez (20691412)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Mst1 knockout or suppressing its kinase activity increases the production of inflammatory mediators by activating the NF-κB pathway. by Jianyang Li (461703)

Subjects:

DataSheet1_Prognostic significance of fludeoxyglucose positron emission tomography delta radiomics following bridging therapy in patients with large B-cell lymphoma undergoing CAR... by Colton Ladbury (19768281)

“…Purpose/objective(s)<p>Bridging radiation therapy (bRT) is increasingly being utilized prior to chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL). …”

Distribution of final population size (A) and mean change in mean MSI over time (B) over 100 simulations for each parameter set shown in Table 3 in the absence of weevils (left) an... by Alexandra M. Campbell (3284094)

Agreement in the order of district towns in the results of the SD-TOPSIS application in space ‐ combination A vs. B1. by Roman Vavrek (13200141)

Data Sheet 1_Prognostic impact of dynamic changes of type I melanoma antigen gene proteins CT7 (MAGE-C1/CT7) transcripts in multiple myeloma.docx by Xuelin Dou (10938549)

“…Our data showed the predictive value of peri-ASCT frontline treatment. A 2-log decrease of MAGE-C1/CT7 post-induction cycle 2 compared to baseline correlated with a negative peri-ASCT MAGE-C1/CT7 status, providing an earlier prognostic marker of treatment response.…”

Agreement with tolerance in the order of district towns in the results of SD-TOPSIS application in space ‐ combination A vs. B1. by Roman Vavrek (13200141)

Polylactic Acid/Polybutylene Adipate Terephthalate-Carbon Nanotube Nanobiocomposites with a Segregated Toughening Morphology Yielding Large Ductility for Biocompatible Materials by Utsab Ayan (18552401)

Oral infection with YFV-Asibi cap0 leads to lower viral loads in the midguts largely diminishing dissemination to secondary tissues. by Anja vom Hemdt (19787189)